<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669796</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1794</org_study_id>
    <nct_id>NCT03669796</nct_id>
  </id_info>
  <brief_title>Marine Protein Hydrolysate as Dietary Supplement in Elderly Part I</brief_title>
  <acronym>MPH-BS</acronym>
  <official_title>A Study of the Effects of Marine Protein Hydrolysate as Dietary Supplement on the Regulation of Postprandial Blood Glucose Metabolism in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Møre og Romsdal HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Møre og Romsdal HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the potential effect of a marine protein hydrolysate
      (MPH) supplement before a meal on postprandial glucose tolerance in healthy subjects, to
      achieve more knowledge on this presumed beneficial, blood glucose lowering effect
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To further investigate the effects of MPH in a single dose of 20 mg/kg of body weight on
      postprandial blood glucose, insulin and GLP-1 (as markers of glucose metabolism) in healthy,
      active middle-aged to elderly subjects - age 40-65 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A double-blind crossover trial, including two different study days, with 4-7 days wash-out (WO) period in between. The intervention implemented 20 mg of MPH per kg body weight (test material) or control (casein).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>First sample fasting baseline, thereafter repeated samples every 20 minutes (i.e.20, 40, 60, 80, 100,120,140 minutes after baseline), last at 200 minutes after baseline.</time_frame>
    <description>Postprandial glucose (mmol/L) change on each day of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>First sample fasting baseline, thereafter repeated samples every 20 minutes (i.e.20, 40, 60, 80, 100,120,140 minutes after baseline), last at 200 minutes after baseline</time_frame>
    <description>Postprandial Insulin (mIE/L) - change on each day of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormon 1</measure>
    <time_frame>First sample fasting baseline, thereafter repeated samples (i.e.20, 40, 60, 100 minutes after baseline), last at 200 minutes after baseline</time_frame>
    <description>Glucagon like peptide 1 (GLP-1) pmol/l change on each day of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>First (baseline) symptomscore (as described above) measured fasting , thereafter repeated symptom score i.e. at 20, 40 minutes after baseline, last symptom score measure at 200 minutes after baseline</time_frame>
    <description>Assessed by questionnaire VAS, scale from 0-10, where 0 is minimum score and 10 is the maximum score, reported e.g. as a total score of 7. The higher the reported value is the worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KANE, symptom score</measure>
    <time_frame>First (baseline) symptom score (as described above) measured fasting and the next measure at 200 minutes after baseline</time_frame>
    <description>Assessed by questionaire KANE (family name) , scale from 0-10, where 0 is minimum score and 10 is the maximum score, reported e.g. as a total score of 7. The higher the reported value is the worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>supplementary Marine protein hydrolysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg powder per kg body weight of Marine protein hydrolysate (MPH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg powder per kg body weight of casein/maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Marine protein hydrolysate (mph)</intervention_name>
    <description>Marine (Cod) protein hydrolysate</description>
    <arm_group_label>supplementary Marine protein hydrolysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Maltodextrin/Casein</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Body mass index (BMI) 20-30

        Exclusion Criteria:

          -  Suspected allergies against fish or shellfish

          -  Low or unstable blood pressure

          -  Diabetes mellitus, treated pharmacological

          -  Chronic diseases or therapies that is likely to interfere with the evaluation of study
             results

          -  Acute infections (may be reconsidered for inclusion at a later time)

          -  Allergic to milk, confirmed diagnose

          -  Pregnancy

          -  Women who are breast-feeding infants

          -  Inability or unwillingness to comply with the requirements of study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Arne Lihaug Hoff, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Møre &amp; Romsdal Hospital Trust, Ålesund Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital, Helse Møre og Romsdal HF</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Lihaug Hoff DA, Lied GA. Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial. J Nutr Sci. 2018 Nov 28;7:e33. doi: 10.1017/jns.2018.23. eCollection 2018. Erratum in: J Nutr Sci. 2019 Jan 18;8:e1.</citation>
    <PMID>30524707</PMID>
  </results_reference>
  <results_reference>
    <citation>Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Hoff DAL, Lied GA. Erratum: Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial - CORRIGENDUM. J Nutr Sci. 2019 Jan 18;8:e1. doi: 10.1017/jns.2018.30. eCollection 2019.</citation>
    <PMID>30719283</PMID>
  </results_reference>
  <results_reference>
    <citation>Dale HF, Jensen C, Hausken T, Lied E, Hatlebakk JG, Brønstad I, Hoff DAL, Lied GA. Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food Nutr Res. 2019 Oct 22;63. doi: 10.29219/fnr.v63.3507. eCollection 2019.</citation>
    <PMID>31692759</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary Supplements</keyword>
  <keyword>Fish Proteins</keyword>
  <keyword>Protein Hydrolysates</keyword>
  <keyword>Aged</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

